IN8BIO, INC. Capital Expenditures Incurred but Not yet Paid
IN8BIO, INC. (INAB) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-08-08
- IN8BIO, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- IN8BIO, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $356.00K.
- IN8BIO, INC. capital expenditures incurred but not yet paid for fiscal 2021 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |
| 2023-12-31 | $0.00 10-K · filed 2024-03-14 | |
| 2023-06-30 | $22.00K 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $356.00K 10-K · filed 2024-03-14 | |
| 2022-06-30 | $1.00K 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |